Skip to main content
Log in

Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Data availability

The data supporting this study’s findings are available from the corresponding author upon reasonable request.

References

  1. Paschka P, Döhner K (2013) Core-binding factor acute myeloid leukemia: can we improve on HiDAC consolidation? Hematol Am Soc Hematol Educ Program 2013:209–219

    Article  Google Scholar 

  2. Schlenk RF, Benner A, Krauter J, Büchner T, Sauerland C et al (2004) Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 22:3741–3750

    Article  CAS  Google Scholar 

  3. Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364:1027–1036

    Article  Google Scholar 

  4. Martin-Broto J, Moura DS (2020) New drugs in gastrointestinal stromal tumors. Curr Opin Oncol 32:314–320

    Article  CAS  Google Scholar 

  5. Guido M, Susan G, Kristina L, Weiqiang Z, Donna B et al (2020) Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801. Blood Advance 4:696–705

    Article  Google Scholar 

  6. Samantha B, Laura CM (2021) Avapritinib in the treatment of systemic mastocytosis: an update. Curr Hematol Malig Rep 16:464–472

    Article  Google Scholar 

  7. Prithviraj B, Srdan V (2021) Avapritinib for systemic mastocytosis. Expert Rev Hematol 14:687–696

    Article  Google Scholar 

Download references

Funding

This study was funded by the grant from the National Key R&D Program of China (2019YFA0111000), the National Natural Science Foundation of China (81900130, 81970136, 81970142, 82000132, 8217011130, 8210010924), the Natural Science Foundation of the Jiangsu Higher Education Institution of China (18KJA320005), the Natural Science Foundation of Jiangsu Province (BK20190180), priority academic program development of Jiangsu Higher Education Institution, the Innovation Capability Development Project of Jiangsu Province (BM215004), the Translational Research Grant of NCRCH (2020WSB03, 2020WSB11, 2020WSB13), and the Open Project of Jiangsu Biobank of Clinical Resources (SBK202003001, SBK202003003).

Author information

Authors and Affiliations

Authors

Contributions

Jia Yin collected and analyzed data and wrote the first draft of the manuscript; Feng Zhu and Zhi-Bo Zhang collected the data and edited the paper; Qian Wang, Xue-Feng He, Qian Wu, and Jing-Ren Zhang provided patient care; Ai-Ning Sun, De-Pei Wu, Xiao-Fei Yang, and Su-Ning Chen designed research, analyzed data, and wrote the manuscript. The submission has been read and approved for submission by all authors.

Corresponding authors

Correspondence to Xiao-Fei Yang or Su-Ning Chen.

Ethics declarations

Ethics approval

This case study has completely complied with the human research regulations and ethical requirements issued by the Ethics Committee of the First Affiliated Hospital of Soochow University.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Jia Yin, Feng Zhu, and Zhi-Bo Zhang are co-first authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yin, J., Zhu, F., Zhang, ZB. et al. Rapid and deep response to avapritinib in heavily treated acute myeloid leukemia with t (8;21) and KIT mutation. Ann Hematol 101, 2347–2350 (2022). https://doi.org/10.1007/s00277-022-04897-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-022-04897-6

Navigation